

### **REMARKS/ARGUMENTS**

The Restriction action dated 6 September 2006 required election between claim groups I-VII. Applicants herein elect claim group VII, including claims 14-17, drawn to a non-human animal comprising an altered or deleted CIRL3-L. Accordingly, non-elected claims 1-13 are cancelled without prejudice or disclaimer.

Claim 14 is amended to add the limitations of subject matter cancelled from claims 15 and 17. Claim 15 is amended to clarify that anxiety-related disorders includes obsessive-compulsive disorder (OCD) and perseverative developmental disabilities (PDDs). Support for this amendment is found in the specification at, for example, paragraph [0008]. Claim 16 and new claim 18 are drawn to PDD and OCD, respectively. Claim 17 is cancelled. New claim 19 identifies PDDs and is supported in the specification at paragraph [0008]. New claim 29 is drawn to the knockin mouse in which the human CIRL3-L gene replaces the endogenous murine gene. Support is found in the specification at, for example, paragraph [0021]. New claims 21-24 are supported by claims 15-19. New claims 25-26 are drawn to a method which utilizes the transgenic mouse of the invention. It is respectfully submitted that the new method claims 25-26 require the use of the elected transgenic mouse and thus will not involve a further search or add to the burden of the search. Accordingly, applicants respectfully request that claims 25-26 be included in the elected group. No new matter is added by the new claims.

### **Conclusion**

It is believed that this document is fully responsive to the Restriction requirement raised in the Restriction action dated 06 September 2006. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

### **Fees**

A 1-month extension of time is requested to extend the period of response from 6 October 2006 to 6 November 2006. Accordingly, the Commissioner is hereby

USSN 10/804,532

Restriction Requirement dated 06 September 2006

Response dated 10 October 2006

authorized to charge Deposit Account Number 18-0650 for the amount of \$120, or any additional fee that may be determined to be due.

Respectfully submitted

A handwritten signature in cursive script, appearing to read "Valeta Gregg", is written over a horizontal line.

Valeta Gregg, Ph.D., Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 593-1077 (direct)